Macro partitioning
Pancreatic lipase inhibitors, specifically Orlistat, reduce obesity by preventing the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides, thereby reducing caloric intake from fat.
Orlistat works by physically blocking your body from absorbing about 25% of the fat you eat. This leads to weight loss, but it comes with a high likelihood of gastrointestinal side effects like oily stools and gas. To minimize these side effects, you must strictly limit the amount of fat in your diet, particularly with each dose. It is a tool for weight management, not a free pass to eat high-fat foods.
By blocking this enzyme, triglycerides are not converted into free fatty acids that can be absorbed, resulting in their excretion without digestion. This process helps reduce the number of calories absorbed from fat, aiding in weight loss.
Why this rating
The paper is a narrative review citing multiple studies, but lacks a single large-scale primary trial with detailed statistical outcomes in the text provided.
Source
Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions
Vetriselvan Subramaniyan et al. · International Journal of Obesity · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →